We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cells Loaded with Prodrug-Containing Microparticles Selectively Destroy Prostate Cancer Tumors

By LabMedica International staff writers
Posted on 02 May 2016
Print article
Image: A confocal microscopy image of stem cells loaded with drug containing polymeric microparticles (Photo courtesy of Jeff Karp and Oren Levy, Brigham and Women\'s Hospital).
Image: A confocal microscopy image of stem cells loaded with drug containing polymeric microparticles (Photo courtesy of Jeff Karp and Oren Levy, Brigham and Women\'s Hospital).
A novel approach to treating metastatic prostate cancer with minimal adverse side effects is based on cellular transport of a harmless prodrug that is activated and becomes toxic only in the vicinity of the tumor microenvironment.

Investigators at Brigham and Women's Hospital (Boston, MA, USA) and colleagues at Johns Hopkins University (Baltimore, MD, USA) loaded human mesenchymal stem cells (MSCs) with poly(lactic-co-glycolic acid) (PLGA) microparticles (MPs) that encapsulated the macromolecule G114, a thapsigargin-based prodrug that was specifically activated by prostate specific antigen (PSA).

Thapsigargin, a sesquiterpene lactone extracted from a plant, Thapsia garganica is a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase. The drug raises cytosolic (intracellular) calcium concentration by blocking the ability of the cell to pump calcium into the sarcoplasmic and endoplasmic reticula. Thapsigargin specifically inhibits the fusion of autophagosomes with lysosomes; the last step in the autophagic process. The inhibition of the autophagic process in turn induces stress on the endoplasmic reticulum, which ultimately leads to cellular death.

The investigators reported in the March 17, 2016, online edition of the journal Biomaterials that G114-particles (approximately 950 nanometers in size) were internalized by MSCs, followed by the release of G114 as an intact prodrug from the loaded cells. G114 released from G114 MP-loaded MSCs selectively induced death of the PSA-secreting prostate cancer cell line, LNCaP.

G114 MP-loaded MSCs inhibited tumor growth when used in proof-of-concept co-inoculation studies with CWR22 prostate cancer xenografts, suggesting that cell-based delivery of G114 did not compromise the potency of this pro-drug in vitro or in vivo.

"The prodrug only becomes toxic in the presence of the tumor microenvironment, which adds another layer of specificity to this targeted delivery system," said contributing author Dr. John Isaacs, professor of urology and oncology at Johns Hopkins University.

"In cancer therapeutics, one of the great challenges is finding how to specifically deliver high doses of chemotherapeutics to a tumor, but minimize the systemic toxicity," said senior author Dr. Jeffrey Karp, associate professor of medicine at Brigham and Women's Hospital.

Related Links:
Brigham and Women's Hospital
Johns Hopkins University
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.